Selling, General, and Administrative Costs: Viatris Inc. vs Ultragenyx Pharmaceutical Inc.

A Tale of Two Companies: SG&A Expenses Over Time

In the ever-evolving pharmaceutical industry, understanding the financial dynamics of companies is crucial. This chart provides a fascinating comparison of Selling, General, and Administrative (SG&A) expenses between Viatris Inc. and Ultragenyx Pharmaceutical Inc. from 2014 to 2023.

Viatris Inc.

Viatris Inc., a global healthcare company, has consistently shown a robust financial footprint. Over the past decade, its SG&A expenses have surged by over 200%, peaking in 2023. This growth reflects Viatris's expansive operational strategies and market presence.

Ultragenyx Pharmaceutical Inc.

In contrast, Ultragenyx, a biopharmaceutical company focused on rare diseases, has seen its SG&A expenses grow nearly 30-fold since 2014. This dramatic increase underscores its aggressive investment in research and development, crucial for its niche market.

Conclusion

This comparison highlights the diverse financial strategies of these two companies, offering insights into their operational priorities and market strategies.